Introduction
In the early accounts of the use of captopril (SQ 14 225), an inhibitor of the enzyme responsible for the conversion of angiotensin I into angiotensin 11, there has been little attention paid to changes in circulating concentrations of angiotensins 1 and I1 during therapy (Case, Atlas, Laragh, Sealey, Sullivan & McKinstry, 1978;  Cody, Tarazi, Bravo & Fouad, 1978;  Gavras, Brunner, Turini, Kershaw, Tim, Cuttelod, Gavras, Vukovich & McKinstry, 1978) . The present study reports a detailed analysis of changes in circulating concentrations of active and total renin, angiotensins I and I1 and aldosterone, and in sodium and potassium status, during oral captopril treatment, in hypertensive subjects with renal artery stenosis and in patients unresponsive to previous therapy.
Methods
Plasma concentrations of active (normal range 10-50 p-units/ml) and total (normal 60-200 punits/ml) renin (Millar, Leckie, Semple, Morton, 139s 140s
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Sonkodi , angiotensin I1 (5-35 pg/ml) (Morton, Semple, Waite, Brown, Lever & Robertson, 1976) and aldosterone (less than 18 ng/100 ml) (Fraser, Guest & Young, 1973) , and blood concentrations of angiotensin I (10-90 pg/ml) , were measured in peripheral venous blood.
Because high concentrations of angiotensin I may accumulate in plasma (and hence in plasma extracts) during captopril administration, crossreaction of angiotensin I with antibodies to angiotensin I1 may give falsely high values for plasma angiotensin I1 . This was corrected for in the earlier studies reported here by chromatography as previously described . In later studies, angiotensin I concentrations were separately measured in plasma extracts, and interference with the plasma angiotensin I1 assay was determined from a graph constructed by adding known concentrations of angiotensin I to a plasma pool and assaying for angiotensin 11; the appropriate correction was then applied.
Blood samples were taken after overnight recumbency and fasting at 09.30 and 10.00 hours, before the initial dose of captopril, and 30 min, 2 h and 6 h subsequently, the patients remaining fasting and recumbent until the 2 h sample had been taken. Patients were again recumbent for 1 h before the 6 h sample. The initial dose of oral captopril was 25 mg (ten cases) or 6.25 mg (three patients). A maximum dose of 450 mg daily was employed long-term. The values given for the various components of the renin-angiotensin-aldosterone system during prolonged therapy are, in the patients with renal artery stenosis, the means obtained in samples taken at 10.00, 12.00and 16.00 h, 150 mg of captopril having been given at 22.00 hours on the previous evening, and again immediately after the 10.00 hours sample. In the patients with drug-resistant hypertension the values are those obtained at 10.00 hours, 12 h after the previous dose of captopril and diuretic.
Exchangeable sodium (Na,), exchangeable potassium (K,) and total body potassium (TBK) were measured by isotope dilution Boddy, King, Tothill & Strong, 1971) ; in one man, total body sodium was measured by activation analysis (Boddy, Brown, Davies, Elliot, Harvey, Haywood, Holloway, Lever, Robertson & Williams, 1978) .
Blood pressures were measured with a clinical sphygmomanometer, after at least 10 min rest, phase V being taken as diastolic.
Because of the wide scatter of results, statistical calculations were performed with non-parametric methods.
Patients
All patients were taking a fixed diet of known and normal sodium and potassium content. Seven patients (two males; age range 16-55 years) had renal ischaemia; five had typical radiological and ureteric catheterization findings of unilateral renal artery stenosis (Brown, Owen, Peart, Robertson & Sutton, 1960) , together with appropriate lateralizing features on renal vein sampling for renin and angiotensin (Millar et al., 1978; Semple, Cumming & Millar, 1979) . One patient had bilateral renal artery stenosis arteriographically, and one, previously in the malignant phase, was presumed to have consequent and predominantly unilateral intrarenal arterial lesions, having normal renal arteriograms, but evidence of unilateral renal ischaemia on renal vein sampling and ureteric catheterization. No patient in this group had received any therapy except bethanidine for 4 weeks before the study.
Six further patients (three males; age range 31-62 years) had severe hypertension unresponsive to a combination of diuretic, B-adrenoreceptor blocker and vasodilator drugs given in optimal dosage. All were receiving this combination immediately before starting captopril.
Results

Patients with renal ischaemia
Three contrasting cases of renal artery stenosis are summarized to emphasize several diverse aspects of captopril therapy.
( i ) A 52 year old woman with severe hypertension (250/135 mmHg) had a unilateral renal artery occlusion, plasma sodium of 123 mmol/l, plasma potassium 2.0 mmol/l, sodium and potassium depletion (Na, 74%, K, 78%, of expected normal; Davies, Schalekamp, Beevers, Brown, Briggs, Lever, Medina, Morton, Robertson & Tree, 1973) , thirst and polyuria. Peripheral plasma concentrations of active renin (900 punitdml), angiotensin I1 (615 pg/ml) and aldosterone (77. ng/100 ml) were grossly elevated. Captopril (25 mg) led to a steep fall in plasma angiotensin 11 to 29 pg/ml within 30 min, and arterial pressure fell to 92/62 mmHg. Subse-141s quently all features of the syndrome were corrected by continued administration of the drug over 8 days; unilateral nephrectomy was then curative.
( Resume' of results in patients with renal artery stenosis. Mean blood pressures (~S E M ) for the 2 days before treatment, and on the morning immediately before the first dose, were respectively 197/112 f 8/6, 200/112 f 10/6 and 187/116 f 11/5 mmHg. Respective readings at 2 h, 6 days and 6 weeks (except in the two patients where captopril alone was discontinued earlier and the last available readings were taken) were: 157/99 f 154/92 f 7/7 mmHg (P < 0.05).
At the same intervals, plasma angiotensin I1 fell from 118.4 f 99 pg/ml to 23.0 f 15.0 (P < 0.05), 25.4 2 17.8 (P < 0.05) and 14.6 2 8.8 pg/ml (P < 0.05); plasma aldosterone fell from 21.6 f 8.7
to 15-0 f 7.5, 10.4 f 1.7 and 7.9 f 1.5 ng/100 ml (P < 0.05).
Na, increased by 598 mmol during 8 days of therapy in the patient with the hyponatraemic syndrome, and total body sodium by 157 mmol during 14 days in the patient resistant to therapy. In the remainder there was no appreciable change in Na, during 6 weeks of treatment (respective means 2239 f 230 and 2172 f 235 mmol). K, increased by 226 mmol during captopril therapy in the hyponatraemic patient. TBK was not significantly altered in the remainder during captopril 13/9 (P < 0*05), 157/93 f 10/7 (P < 0.05) and treatment (respective means 2413 f 194 and 2287 f 162 mmol). Plasma sodium concentration was unchanged during 6 weeks of treatment (respective means 137-6 f 2.4 and 137.8 f 1-2 mmol/l).
Plasma K+ rose marginally from 3.8 f 0.4 to 4.4 f 0.3 mmol/l (0.05 < P < 0.1); hyperkalaemia was not seen.
Patients with resistant hypertension
Captopril alone (final dose 450 mg/day) did not significantly reduce arterial pressure (mean 215/116 f. 11/8 and 199/114 f 15/8 mmHg before and during therapy), although plasma angiotensin I1 fell from 39.8 f 15.9 to 11.9 f 2.7 pg/ml (P < 0.05). When either hydrochlorothiazide (50 mg twice daily) or frusemide (from 40 to 1500 mg/day) was added to captopril, arterial pressure was clearly lowered, being 153/93 f l0/6 mmHg (P < 0.05) from 3 to 26 days later, with optimal diuretic dosage. With continued treatment for 3 months, blood pressure remained well-controlled (140/90 f 8/2 mmHg; P < 0.05) and plasma angiotensin I1 suppressed (7.3 f 2.4 pg/ml). Plasma aldosterone did not increase with the addition of a diuretic to captopril (mean values 13.0 f 2.6 ng/100 ml before treatment; 7.9 f. 1.4 ng/100 ml on captopril alone; 10.4 f 1.4 ng/100 ml on combination therapy). Treatment has now continued up to 9 months in this group with no loss of control.
Resume' of changes 2 h and 6 weeks sfter initial dose of captopril Changes at 2 h. Fig. 1 summarizes the response at 2 h to the initial dose of captopril (25 mg in 10 patients, 6.25 mg in three). There were highly significant falls in systolic and diastolic pressures, plasma angiotensin I1 and plasma aldosterone, and increases in the plasma concentrations of active and total r e i n and blood concentration of angiotensin I. There was a highly significant correlation between the fall in plasma angiotensin I1 and the fall in diastolic pressure (rs = 0.73; P < 0.01) and, less closely, between the fall in plasma angiotensin I1 and mean blood pressure (rs = 0.49; Changes at 6 weeks. Seven patients have been studied after at least 6 weeks of treatment with captopril (450 mg/day); five were on captopril alone and two were also receiving diuretics. While plasma concentrations of active renin (794.3 f 22.0 vs P < 0.05). pre-captopril mean of 74.6 f 13.8 ,u-units/ml; P < 14.2 pg/ml; P < 0.05) continued elevated, plasma angiotensin I1 remained suppressed (5.0 _+ 0.8 vs 19.9 _+ 3.6 pg/ml; P < 0.05).
Side-effecls
Two patients developed symptomatic sinus tachycardia (up to 160 beatdmin) on standing, one while on captopril alone and one after hydrochlorothiazide was added. Two others had a temporary disturbance of taste. Particularly in patients with tenal impairment serum urea and creatinine tended to rise when frusemide was added, and this should therefore be monitored closely.
Discussion
In normal subjects and in hypertensive patients, peripheral plasma concentrations of angiotensin I1 are within a range in which small changes are capable of affecting arterial pressure (Chinn & Diisterdieck, 1972 Swales, 1979) . The evidence obtained herein does not suggest that overall sodium retention participates, because no fall in Na, was seen when blood pressure was controlled with captopril in renal artery stenosis. The close interdependence of sodium status and angiotensin I1 in blood pressure maintenance is emphasized again in this study. Sodium retention was observed in the patient with renal artery stenosis resistant to captopril; pressure fell promptly when frusemide was added. In the hyponatraemic sodium-depleted woman, pressure fell steeply when captopril was given. Moreover, the combination of captopril with a natriuretic durg successfully controlled arterial pressure in every patient previously resistant to treatment.
Significant side-effects were seen, although they were not so severe as to require treatment to be stopped. In view of these adverse reactions, however, captopril should be used with caution, particularly in moderate hypertension.
